AdvanTIG-203: results and biomarkers in esophageal cancer
Nature Communications · Published 2026-09-18
A randomized phase II trial evaluates dual checkpoint blockade and exploratory immune biomarkers in advanced esophageal squamous cell carcinoma.
The 125-patient trial did not meet its primary objective-response endpoint. Adding ociperlimab to tislelizumab did not significantly improve efficacy. Exploratory analyses identified immune-inflamed signatures that warrant further investigation.
Qi Zhao’s role: Co-author, Sun Yat-sen University Cancer Center.
Source: publication record. Checked on 19 November 2026.